No Data
No Data
SinoMab BioScience's H1 Loss Narrows as Revenue Rises; Shares Fall 15%
China Antibody-B (03681) released its interim performance with a revenue of 2.026 million yuan, a year-on-year increase of 48.4%.
China Antibody-B (03681) released its six-month performance ending on June 30, 2024, with revenue of 202.6 million...
China Antibody-B (03681.HK) reduced its mid-year losses to 90.6 million yuan.
On August 19th, Gelonghui announced that as of June 30th, 2024, the total amount of other income and gains reported by the company for the six-month period was approximately RMB 43 million, a decrease of approximately RMB 28 million from the same period last year, mainly due to a reduction in government subsidies of approximately RMB 23 million. The loss for the period decreased by RMB 43.5 million, from RMB 134.1 million in the same period last year to RMB 90.6 million in the current period, mainly due to (i) the BLA acceptance of Syzilumab in September 2023 and (ii) the launch of Syzilumab in 2024.
Express News | SinoMab BioScience - Hy Revenue RMB2 Mln Vs RMB1.4 Mln
Express News | SinoMab BioScience Ltd - Hy Loss RMB90.6 Mln
SINOMAB BIO-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024AND CHANGE IN USE OF PROCEEDS
No Data